Mirum Pharmaceuticals Stock Surges 25%, With A 9-Day Winning Spree
Mirum Pharmaceuticals (MIRM) – a developer of oral therapies for rare liver diseases – hit a 9-day winning streak, with cumulative gains over this period amounting to 25%. The company’s market cap has surged by about $1.4 Bil over the last 9 days and currently stands at $7.3 Bil.
Is this an opportunity or a trap? There are only a couple of things to fear in MIRM stock given its overall Strong operating performance and financial condition. But given its Very High valuation, the stock appears Relatively Expensive (For details, see Buy or Sell MIRM).
But here is the interesting part. You are reading about this 25% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- How One Project Funnel Reframes The Sunbelt Rentals Stock Story
- What Future Earnings Are QQQM’s Companies Forecasting?
- XBI Ignored The Market’s Downturn
- Your VB Position Is At A Record High. Don’t Overthink It.
- Uber Stock And The Growth Rate That Matters Most
- Accenture Stock Is Under Pressure. Its Biggest Clients Tell A Different Story.
The following table summarizes the return for MIRM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MIRM | S&P 500 |
|---|---|---|
| 1D | 5.5% | -0.0% |
| 9D (Current Streak) | 24.6% | -1.0% |
| 1M (21D) | 27.2% | -2.2% |
| 3M (63D) | 39.3% | 13.5% |
| YTD 2026 | 56.7% | 7.4% |
| 2025 | 91.0% | 16.4% |
| 2024 | 40.1% | 23.3% |
| 2023 | 51.4% | 24.2% |
However, big gains can follow sharp reversals – but how has MIRM behaved after prior drops? See MIRM Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 138 S&P constituents with 3 days or more of consecutive gains and 37 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 32 | 15 |
| 4D | 49 | 9 |
| 5D | 33 | 8 |
| 6D | 23 | 2 |
| 7D or more | 1 | 3 |
| Total >=3 D | 138 | 37 |
Key Financials for Mirum Pharmaceuticals (MIRM)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $336.9 Mil | $521.3 Mil |
| Operating Income | $-87.6 Mil | $-22.1 Mil |
| Net Income | $-87.9 Mil | $-23.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $148.9 Mil | $159.9 Mil |
| Operating Income | $-4.6 Mil | $-63.2 Mil |
| Net Income | $-5.7 Mil | $-790.2 Mil |
While MIRM stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.